SeaStar Medical Holding Corporation
ICUHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeSeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The $15.4M market capitalization puts ICU squarely in micro-cap range for its industry. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
Market Cap
$15.4M
Beta
-1.03
P/E (TTM)
—
P/E (Fwd)
-1.50
EPS (TTM)
$-2.36
EPS (Fwd)
$-2.57
ROE
-302.0%
ROA
-79.2%
Cash
$9.3M
Total Debt
$331,000
Free CF
-$9.6M
52W Change
-49.6%
Annual Financials
Cash vs Debt
Where ICU stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ICU finished 48.15% above its 150-day moving average ($3.24) and 29.73% above its 200-day moving average ($3.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ICU overbought or oversold?
At the July 15, 2026 close, ICU's RSI(14) was 70.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $9.3M in cash comfortably exceeding the $331K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$9.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -302.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, SeaStar Medical Holding Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, ICU has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence SeaStar Medical Holding Corporation's trajectory.